{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:31:10Z","timestamp":1793345470611,"version":"4.5.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02025","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:34:35Z","timestamp":1568374475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":91,"title":["The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Dan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2013.00167","article-title":"New Insights in the Immunobiology of IL-1 Family Members","volume":"4","author":"van de Veerdonk","year":"2013","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1007\/s12272-016-0855-0","article-title":"Intracellular interleukin (IL)-1 family cytokine processing enzyme","volume":"39","author":"Kwak","year":"2016","journal-title":"Arch Pharm Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/cyto.2002.0873","article-title":"Interleukin-1F7B (IL-1H4\/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-\u03b3 production","volume":"18","author":"Kumar","year":"2002","journal-title":"Cytokine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.smim.2013.10.001","article-title":"Overview of the interleukin-1 family of ligands and receptors","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity."},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"van de Veerdonk","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12026-016-8797-7","article-title":"Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol Res."},{"key":"B14","first-page":"81","article-title":"Interleukin 1\u03b1 single-nucleotide polymorphism associated with systemic sclerosis","volume":"31","author":"Hutyrova","year":"2004","journal-title":"J Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/art.10736","article-title":"Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population","volume":"48","author":"Kawaguchi","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/iji.12212","article-title":"IL-1A rs1800587, IL-1B rs1143634 and IL-1R1 rs2234650 polymorphisms in Iranian patients with systemic sclerosis","volume":"42","author":"Abtahi","year":"2015","journal-title":"Int J Immunogenet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0198693","DOI":"10.1371\/journal.pone.0198693","article-title":"Meta-analyses of IL1A polymorphisms and the risk of several autoimmune diseases published in databases","volume":"13","author":"Su","year":"2018","journal-title":"PLoS ONE."},{"key":"B18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.humimm.2007.03.005","article-title":"Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology","volume":"68","author":"Beretta","year":"2007","journal-title":"Hum Immunol."},{"key":"B19","first-page":"997","article-title":"Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis","volume":"34","author":"Mattuzzi","year":"2007","journal-title":"J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/art.23836","article-title":"Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients","volume":"59","author":"Beretta","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00296-015-3417-8","article-title":"The IL-33 gene is related to increased susceptibility to systemic sclerosis","volume":"36","author":"Koca","year":"2016","journal-title":"Rheumatol Int."},{"key":"B22","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.4049\/jimmunol.163.7.3969","article-title":"Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha","volume":"163","author":"Higgins","year":"1999","journal-title":"J Immunol."},{"key":"B23","first-page":"1946","article-title":"Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts","volume":"31","author":"Kawaguchi","year":"2004","journal-title":"J Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1002\/cti2.1045","article-title":"Analysis of serum interleukin(IL)-1\u03b1, IL-1\u03b2 and IL-18 in patients with systemic sclerosis","volume":"8","author":"Lin","year":"2019","journal-title":"Clin Transl Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1\u03b1 from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"J Clin Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1600-6143.2009.02706.x","article-title":"Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection","volume":"9","author":"Diaz","year":"2009","journal-title":"Am J Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12239","DOI":"10.1074\/jbc.M413284200","article-title":"Interleukin-6 regulation of transforming growth factor (TGF)-\u03b2 receptor compartmentalization and turnover enhances TGF-\u03b21 signaling","volume":"280","author":"Zhang","year":"2005","journal-title":"J Biol Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2013at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor \u03b2 in tissue fibrosis","volume":"331","author":"Border","year":"1994","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10008","DOI":"10.1073\/pnas.1737765100","article-title":"A nuclear target for interleukin-1\u03b1: interaction with the growth suppressor necdin modulates proliferation and collagen expression","volume":"100","author":"Hu","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1006\/bbrc.1999.0155","article-title":"IL-1 rescues scleroderma myofibroblasts from serum-starvation-induced cell death","volume":"255","author":"Kirk","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/intimm\/dxg054","article-title":"IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response","volume":"15","author":"Nakae","year":"2003","journal-title":"Int Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1002\/eji.200425452","article-title":"Inter- leukin 1 plays a major role in the development of Th2- mediated immunity","volume":"34","author":"Helmby","year":"2004","journal-title":"Eur J Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/jcp.2004.019224","article-title":"Alterations of mononuclear inflammatory cells, CD4\/CD8+ T cells, interleukin 1\u03b2, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis","volume":"58","author":"Hussein","year":"2005","journal-title":"J Clin Pathol."},{"key":"B36","first-page":"5","article-title":"Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients","volume":"17","author":"Martinez-Godinez","year":"2015","journal-title":"Isr Med Assoc J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1172\/JCI12568","article-title":"Transient expression of IL-1\u03b2 induces acute lung injury and chronic repair leading to pulmonary fibrosis","volume":"107","author":"Kolb","year":"2001","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jhep.2011.01.048","article-title":"Lack of interleukin-1\u03b1 or interleukin-1\u03b2 inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice","volume":"55","author":"Kamari","year":"2011","journal-title":"J Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gfp214","article-title":"IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis","volume":"24","author":"Jones","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","article-title":"The role of IL-1 in the pathogenesis of heart disease","volume":"57","author":"Bujak","year":"2009","journal-title":"Arch Immunol Ther Exp."},{"key":"B41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.imbio.2012.05.026","article-title":"IL-1\u03b2 and TGF\u03b22 synergistically induce endothelial to mesenchymal transition in an NFkappaB-dependent manner","volume":"218","author":"Maleszewska","year":"2013","journal-title":"Immunobiology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1\u03b2-mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J Exp Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.30568","article-title":"The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis","volume":"63","author":"Artlett","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13075-017-1331-z","article-title":"Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis","volume":"19","author":"Artlett","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.jid.5700097","article-title":"Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis","volume":"126","author":"Kanangat","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/s10165-011-0480-1","article-title":"Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33","volume":"22","author":"Kageyama","year":"2012","journal-title":"Mod Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","article-title":"Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus","volume":"49","author":"Mok","year":"2010","journal-title":"Rheumatology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.imlet.2009.11.001","article-title":"IL-33 is upregulated in colonocytes of ulcerative colitis","volume":"128","author":"Seidelin","year":"2010","journal-title":"Immunol Lett."},{"key":"B49","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","article-title":"Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis","volume":"72","author":"Terras","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.0903306","article-title":"IL-33 induces IL-13-dependent cutaneous fibrosis","volume":"184","author":"Rankin","year":"2010","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbrep.2016.02.002","article-title":"Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells","volume":"5","author":"Hayakawa","year":"2016","journal-title":"Biochem Biophys Rep."},{"key":"B56","first-page":"19","article-title":"Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production","volume":"10","author":"Mosaad","year":"2003","journal-title":"Egypt J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1165\/rcmb.2003-0306OC","article-title":"Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis","volume":"31","author":"Kitasato","year":"2004","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1440-1797.2006.00737.x","article-title":"Effects of interleukin 18 on injury and activation of human proximal tubular epithelial cells","volume":"12","author":"Liang","year":"2007","journal-title":"Nephrology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"L280","DOI":"10.1152\/ajplung.00380.2004","article-title":"Protection against bleomycin-induced lung injury by IL-18 in mice","volume":"289","author":"Nakatani-Okuda","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/jid.2009.302","article-title":"IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway","volume":"130","author":"Kim","year":"2010","journal-title":"J Invest Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1681\/ASN.2016080840","article-title":"IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23\/IL-17 axis in renal inflammation and fibrosis","volume":"28","author":"Chi","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/MPA.0000000000000765","article-title":"Interleukin-36\u03b1 induces inflammatory mediators from human pancreatic myofibroblasts via a MyD88 dependent pathway","volume":"46","author":"Nishida","year":"2017","journal-title":"Pancreas."},{"key":"B63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36 \u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"19588","DOI":"10.3390\/molecules201019588","article-title":"Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus","volume":"20","author":"Chu","year":"2015","journal-title":"Molecules."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/rheumatology\/kex348","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"56","author":"Cavalli","year":"2017","journal-title":"Rheumatology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.4049\/jimmunol.1300047","article-title":"IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production","volume":"192","author":"Teng","year":"2014","journal-title":"J Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.resinv.2017.06.001","article-title":"Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis","volume":"55","author":"Tominaga","year":"2017","journal-title":"Respir Investig."},{"key":"B68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.rdc.2004.01.005","article-title":"Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis","volume":"30","author":"Cohen","year":"2003","journal-title":"J Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol."},{"key":"B70","first-page":"146","article-title":"Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial","volume":"36","author":"Mantero","year":"2018","journal-title":"Clin Exp Rheumatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T07:05:43Z","timestamp":1695193543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2019.02025"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02025","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"article-number":"2025"}}